18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer

Ugo De Giorgi, Michal Mego, Eric M. Rohren, Ping Liu, Beverly C. Handy, James M. Reuben, Homer A. Macapinlac, Gabriel N. Hortobagyi, Massimo Cristofanilli, Naoto T. Ueno

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Our objective was to compare the predictive significance of 18 F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy. Methods: Breast cancer patients with progressive bone-only metastatic disease without visceral metastases starting a new line of systemic therapy underwent 18 F-FDG PET/CT and had CTC counts determined before and during treatment. Disease status was reassessed by CTC count (≥5 vs. <5 CTC/7.5 mL of blood) and 18 F-FDG PET/CT approximately 2-4 mo after initiation of the new systemic therapy. Results: CTC counts at follow-up agreed with the 18 F-FDG PET/CT assessment in 43 (78%) of the 55 evaluable patients. Of the 12 patients with discordant CTC and 18 F-FDG PET/CT results, 8 (66%) had ≥5 CTCs, with no evidence of progressive disease at the time of the 18 F-FDG PET/CT study, whereas 4 (33%) had <5 CTCs, with evidence of progressive disease by 18 F-FDG PET/CT. 18 F-FDG PET/CT findings and follow-up CTC counts were found to be significantly associated with both progression-free survival (P = 0.02 and P < 0.0001, respectively) and overall survival (P = 0.02 and P = 0.01, respectively). In multivariate analysis, the 18 F-FDG PET/CT assessment remained as the only predictive factor for progression-free survival (P < 0.0001), whereas estrogen receptor status was the only predictive factor for overall survival (P = 0.01). Conclusion: 18 F-FDG PET/CT is a useful tool for therapeutic monitoring in patients with bone metastases from breast cancer. Prospective studies are needed to define the role of 18 F-FDG PET/CT and CTC in the setting of response discordance to establish bone-dominant disease as a tumor-response measurable disease. COPYRIGHT

Original languageEnglish (US)
Pages (from-to)1213-1218
Number of pages6
JournalJournal of Nuclear Medicine
Volume51
Issue number8
DOIs
StatePublished - Aug 1 2010

Fingerprint

Circulating Neoplastic Cells
Cell Count
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Therapeutics
Disease-Free Survival
Survival
Bone Diseases
Physiologic Monitoring
Estrogen Receptors
Multivariate Analysis
Prospective Studies

Keywords

  • Bone metastases
  • Breast cancer
  • Circulating tumor cells
  • PET/CT
  • Therapeutic monitoring

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

De Giorgi, Ugo ; Mego, Michal ; Rohren, Eric M. ; Liu, Ping ; Handy, Beverly C. ; Reuben, James M. ; Macapinlac, Homer A. ; Hortobagyi, Gabriel N. ; Cristofanilli, Massimo ; Ueno, Naoto T. / 18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 8. pp. 1213-1218.
@article{21f512dce2354418a6edbfe9192df3af,
title = "18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer",
abstract = "Our objective was to compare the predictive significance of 18 F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy. Methods: Breast cancer patients with progressive bone-only metastatic disease without visceral metastases starting a new line of systemic therapy underwent 18 F-FDG PET/CT and had CTC counts determined before and during treatment. Disease status was reassessed by CTC count (≥5 vs. <5 CTC/7.5 mL of blood) and 18 F-FDG PET/CT approximately 2-4 mo after initiation of the new systemic therapy. Results: CTC counts at follow-up agreed with the 18 F-FDG PET/CT assessment in 43 (78{\%}) of the 55 evaluable patients. Of the 12 patients with discordant CTC and 18 F-FDG PET/CT results, 8 (66{\%}) had ≥5 CTCs, with no evidence of progressive disease at the time of the 18 F-FDG PET/CT study, whereas 4 (33{\%}) had <5 CTCs, with evidence of progressive disease by 18 F-FDG PET/CT. 18 F-FDG PET/CT findings and follow-up CTC counts were found to be significantly associated with both progression-free survival (P = 0.02 and P < 0.0001, respectively) and overall survival (P = 0.02 and P = 0.01, respectively). In multivariate analysis, the 18 F-FDG PET/CT assessment remained as the only predictive factor for progression-free survival (P < 0.0001), whereas estrogen receptor status was the only predictive factor for overall survival (P = 0.01). Conclusion: 18 F-FDG PET/CT is a useful tool for therapeutic monitoring in patients with bone metastases from breast cancer. Prospective studies are needed to define the role of 18 F-FDG PET/CT and CTC in the setting of response discordance to establish bone-dominant disease as a tumor-response measurable disease. COPYRIGHT",
keywords = "Bone metastases, Breast cancer, Circulating tumor cells, PET/CT, Therapeutic monitoring",
author = "{De Giorgi}, Ugo and Michal Mego and Rohren, {Eric M.} and Ping Liu and Handy, {Beverly C.} and Reuben, {James M.} and Macapinlac, {Homer A.} and Hortobagyi, {Gabriel N.} and Massimo Cristofanilli and Ueno, {Naoto T.}",
year = "2010",
month = "8",
day = "1",
doi = "10.2967/jnumed.110.076455",
language = "English (US)",
volume = "51",
pages = "1213--1218",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

De Giorgi, U, Mego, M, Rohren, EM, Liu, P, Handy, BC, Reuben, JM, Macapinlac, HA, Hortobagyi, GN, Cristofanilli, M & Ueno, NT 2010, '18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer ', Journal of Nuclear Medicine, vol. 51, no. 8, pp. 1213-1218. https://doi.org/10.2967/jnumed.110.076455

18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer . / De Giorgi, Ugo; Mego, Michal; Rohren, Eric M.; Liu, Ping; Handy, Beverly C.; Reuben, James M.; Macapinlac, Homer A.; Hortobagyi, Gabriel N.; Cristofanilli, Massimo; Ueno, Naoto T.

In: Journal of Nuclear Medicine, Vol. 51, No. 8, 01.08.2010, p. 1213-1218.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer

AU - De Giorgi, Ugo

AU - Mego, Michal

AU - Rohren, Eric M.

AU - Liu, Ping

AU - Handy, Beverly C.

AU - Reuben, James M.

AU - Macapinlac, Homer A.

AU - Hortobagyi, Gabriel N.

AU - Cristofanilli, Massimo

AU - Ueno, Naoto T.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Our objective was to compare the predictive significance of 18 F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy. Methods: Breast cancer patients with progressive bone-only metastatic disease without visceral metastases starting a new line of systemic therapy underwent 18 F-FDG PET/CT and had CTC counts determined before and during treatment. Disease status was reassessed by CTC count (≥5 vs. <5 CTC/7.5 mL of blood) and 18 F-FDG PET/CT approximately 2-4 mo after initiation of the new systemic therapy. Results: CTC counts at follow-up agreed with the 18 F-FDG PET/CT assessment in 43 (78%) of the 55 evaluable patients. Of the 12 patients with discordant CTC and 18 F-FDG PET/CT results, 8 (66%) had ≥5 CTCs, with no evidence of progressive disease at the time of the 18 F-FDG PET/CT study, whereas 4 (33%) had <5 CTCs, with evidence of progressive disease by 18 F-FDG PET/CT. 18 F-FDG PET/CT findings and follow-up CTC counts were found to be significantly associated with both progression-free survival (P = 0.02 and P < 0.0001, respectively) and overall survival (P = 0.02 and P = 0.01, respectively). In multivariate analysis, the 18 F-FDG PET/CT assessment remained as the only predictive factor for progression-free survival (P < 0.0001), whereas estrogen receptor status was the only predictive factor for overall survival (P = 0.01). Conclusion: 18 F-FDG PET/CT is a useful tool for therapeutic monitoring in patients with bone metastases from breast cancer. Prospective studies are needed to define the role of 18 F-FDG PET/CT and CTC in the setting of response discordance to establish bone-dominant disease as a tumor-response measurable disease. COPYRIGHT

AB - Our objective was to compare the predictive significance of 18 F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy. Methods: Breast cancer patients with progressive bone-only metastatic disease without visceral metastases starting a new line of systemic therapy underwent 18 F-FDG PET/CT and had CTC counts determined before and during treatment. Disease status was reassessed by CTC count (≥5 vs. <5 CTC/7.5 mL of blood) and 18 F-FDG PET/CT approximately 2-4 mo after initiation of the new systemic therapy. Results: CTC counts at follow-up agreed with the 18 F-FDG PET/CT assessment in 43 (78%) of the 55 evaluable patients. Of the 12 patients with discordant CTC and 18 F-FDG PET/CT results, 8 (66%) had ≥5 CTCs, with no evidence of progressive disease at the time of the 18 F-FDG PET/CT study, whereas 4 (33%) had <5 CTCs, with evidence of progressive disease by 18 F-FDG PET/CT. 18 F-FDG PET/CT findings and follow-up CTC counts were found to be significantly associated with both progression-free survival (P = 0.02 and P < 0.0001, respectively) and overall survival (P = 0.02 and P = 0.01, respectively). In multivariate analysis, the 18 F-FDG PET/CT assessment remained as the only predictive factor for progression-free survival (P < 0.0001), whereas estrogen receptor status was the only predictive factor for overall survival (P = 0.01). Conclusion: 18 F-FDG PET/CT is a useful tool for therapeutic monitoring in patients with bone metastases from breast cancer. Prospective studies are needed to define the role of 18 F-FDG PET/CT and CTC in the setting of response discordance to establish bone-dominant disease as a tumor-response measurable disease. COPYRIGHT

KW - Bone metastases

KW - Breast cancer

KW - Circulating tumor cells

KW - PET/CT

KW - Therapeutic monitoring

UR - http://www.scopus.com/inward/record.url?scp=77956194618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956194618&partnerID=8YFLogxK

U2 - 10.2967/jnumed.110.076455

DO - 10.2967/jnumed.110.076455

M3 - Article

C2 - 20660382

AN - SCOPUS:77956194618

VL - 51

SP - 1213

EP - 1218

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -